An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia

Authors

Taniawati Supali, Universitas Indonesia
Yenny Djuardi, Universitas Indonesia
Michael Christian, Universitas Indonesia
Elisa Iskandar, Universitas Indonesia
Rahmat Alfian, Universitas Indonesia
Roospita Maylasari, Universitas Indonesia
Yossi Destani, Universitas Indonesia
Adriani Lomiga, Universitas Nusa Cendana
Dominikus Minggu, Nusa Tenggara Timur Provincial Health Office
Daphne Lew, Washington University School of Medicine in St. Louis
Joshua Bogus, Washington University School of Medicine in St. Louis
Gary J Weil, Washington University School of Medicine in St. Louis
Peter U. Fischer, Washington University School of Medicine in St. Louis

Journal

PLoS Neglected Tropical Diseases

Publication Date

2021

Document Type

Open Access Publication

Recommended Citation

Supali, Taniawati; Djuardi, Yenny; Christian, Michael; Iskandar, Elisa; Alfian, Rahmat; Maylasari, Roospita; Destani, Yossi; Lomiga, Adriani; Minggu, Dominikus; Lew, Daphne; Bogus, Joshua; Weil, Gary J; and Fischer, Peter U., "An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia." PLoS Neglected Tropical Diseases. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10095